146 related articles for article (PubMed ID: 35737155)
21. Case Report: Identification of a novel
Yu QX; Zhao WJ; Wang HY; Zhang L; Qin L; Zhang L; Han JL
Front Oncol; 2023; 13():1123812. PubMed ID: 37188179
[No Abstract] [Full Text] [Related]
22. The DNA rearrangement that generates the TRK-T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain.
Greco A; Mariani C; Miranda C; Lupas A; Pagliardini S; Pomati M; Pierotti MA
Mol Cell Biol; 1995 Nov; 15(11):6118-27. PubMed ID: 7565764
[TBL] [Abstract][Full Text] [Related]
23. Pan-tropomyosin receptor kinase immunoreactivity, ETV6-NTRK3 fusion subtypes, and RET rearrangement in salivary secretory carcinoma.
Yamamoto H; Nozaki Y; Sugii A; Taguchi K; Hongo T; Jiromaru R; Sato M; Nakano T; Hashimoto K; Fujiwara M; Oda Y
Hum Pathol; 2021 Mar; 109():37-44. PubMed ID: 33301751
[TBL] [Abstract][Full Text] [Related]
24. Chromosome 1 rearrangements involving the genes TPR and NTRK1 produce structurally different thyroid-specific TRK oncogenes.
Greco A; Miranda C; Pagliardini S; Fusetti L; Bongarzone I; Pierotti MA
Genes Chromosomes Cancer; 1997 Jun; 19(2):112-23. PubMed ID: 9172002
[TBL] [Abstract][Full Text] [Related]
25. A sequence analysis of the genomic regions involved in the rearrangements between TPM3 and NTRK1 genes producing TRK oncogenes in papillary thyroid carcinomas.
Butti MG; Bongarzone I; Ferraresi G; Mondellini P; Borrello MG; Pierotti MA
Genomics; 1995 Jul; 28(1):15-24. PubMed ID: 7590742
[TBL] [Abstract][Full Text] [Related]
26. Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy.
Hsiao SJ; Zehir A; Sireci AN; Aisner DL
J Mol Diagn; 2019 Jul; 21(4):553-571. PubMed ID: 31075511
[TBL] [Abstract][Full Text] [Related]
27. Low frequency of rearrangement of TRK protooncogene in Chinese thyroid tumors.
Kuo CS; Lin CY; Hsu CW; Lee CH; Lin HD
Endocrine; 2000 Dec; 13(3):341-4. PubMed ID: 11216646
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemistry with a pan-TRK antibody distinguishes secretory carcinoma of the salivary gland from acinic cell carcinoma.
Hung YP; Jo VY; Hornick JL
Histopathology; 2019 Jul; 75(1):54-62. PubMed ID: 30801752
[TBL] [Abstract][Full Text] [Related]
29. NTRK fusion analysis reveals enrichment in Middle Eastern BRAF wild-type PTC.
Kong Y; Bu R; Parvathareddy SK; Siraj AK; Siraj N; Al-Sobhi SS; Al-Dayel F; Al-Kuraya KS
Eur J Endocrinol; 2021 Apr; 184(4):503-511. PubMed ID: 33524004
[TBL] [Abstract][Full Text] [Related]
30. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D; Besse B; Chawla SP; Bazhenova L; Krauss JC; Chae YK; Barve M; Garrido-Laguna I; Liu SV; Conkling P; John T; Fakih M; Sigal D; Loong HH; Buchschacher GL; Garrido P; Nieva J; Steuer C; Overbeck TR; Bowles DW; Fox E; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Demetri GD;
Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007
[TBL] [Abstract][Full Text] [Related]
31. A Case of Papillary Thyroid Carcinoma and Kostmann Syndrome: A Genomic Theranostic Approach for Comprehensive Treatment.
Han S; Ehrhardt J; Shukla S; Elkbuli A; Nikiforov YE; Gulec SA
Am J Case Rep; 2019 Jul; 20():1027-1034. PubMed ID: 31308356
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathological findings of pediatric NTRK fusion mesenchymal tumors.
Kang J; Park JW; Won JK; Bae JM; Koh J; Yim J; Yun H; Kim SK; Choi JY; Kang HJ; Kim WS; Shin JH; Park SH
Diagn Pathol; 2020 Sep; 15(1):114. PubMed ID: 32957984
[TBL] [Abstract][Full Text] [Related]
33. How Sensitive is Pan-TRK Immunohistochemistry for Detecting NTRK Fusions in Papillary Thyroid Carcinoma?
Hang JF; Lee YC
Mod Pathol; 2023 Jul; 36(7):100222. PubMed ID: 37336120
[No Abstract] [Full Text] [Related]
34. Mediators of receptor tyrosine kinase activation in infantile fibrosarcoma: a Children's Oncology Group study.
Gadd S; Beezhold P; Jennings L; George D; Leuer K; Huang CC; Huff V; Tognon C; Sorensen PH; Triche T; Coffin CM; Perlman EJ
J Pathol; 2012 Sep; 228(1):119-30. PubMed ID: 22374738
[TBL] [Abstract][Full Text] [Related]
35. Targeting TRK family proteins in cancer.
Khotskaya YB; Holla VR; Farago AF; Mills Shaw KR; Meric-Bernstam F; Hong DS
Pharmacol Ther; 2017 May; 173():58-66. PubMed ID: 28174090
[TBL] [Abstract][Full Text] [Related]
36. Pan-tumor screening for NTRK gene fusions using pan-TRK immunohistochemistry and RNA NGS fusion panel testing.
Koehne de González A; Mansukhani MM; Fernandes H; Hsiao SJ
Cancer Genet; 2022 Apr; 262-263():47-52. PubMed ID: 35007853
[TBL] [Abstract][Full Text] [Related]
37. Limited Accuracy of Pan-Trk Immunohistochemistry Screening for
Macerola E; Proietti A; Poma AM; Vignali P; Sparavelli R; Ginori A; Basolo A; Elisei R; Santini F; Basolo F
Int J Mol Sci; 2022 Jul; 23(13):. PubMed ID: 35806472
[TBL] [Abstract][Full Text] [Related]
38. Locally Recurrent Secretory Carcinoma of the Breast with NTRK3 Gene Fusion.
Mortensen L; Ordulu Z; Dagogo-Jack I; Bossuyt V; Winters L; Taghian A; Smith BL; Ellisen LW; Kiedrowski LA; Lennerz JK; Bardia A; Spring LM
Oncologist; 2021 Oct; 26(10):818-824. PubMed ID: 34176200
[TBL] [Abstract][Full Text] [Related]
39. ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours.
Yamamoto H; Yoshida A; Taguchi K; Kohashi K; Hatanaka Y; Yamashita A; Mori D; Oda Y
Histopathology; 2016 Jul; 69(1):72-83. PubMed ID: 26647767
[TBL] [Abstract][Full Text] [Related]
40. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma.
Knezevich SR; McFadden DE; Tao W; Lim JF; Sorensen PH
Nat Genet; 1998 Feb; 18(2):184-7. PubMed ID: 9462753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
